Celldex has added another round of positive data demonstrating that its brain cancer vaccine rindopepimut–more formally called Rintega and less formally “rindo”–provided a clear though relatively modest average survival benefit for recurrent glioblastoma patients in a Phase II study. And with the initial data set from Phase III looming later in the year, the biotech is carefully moving forward with its ongoing dialogue with regulators to gauge just how receptive they may be to speeding up an approval.

…read more

Source: ASCO: Celldex’s glioblastoma vaccine scores a clear survival benefit


0 No comments